Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Paresthesia 1Neurotoxicity Syndromes 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Breast Neoplasms 1Breast Diseases 1Adenocarcinoma of Lung 1

Interventions

exemestane 4entinostat 4Fulvestrant 4ribociclib 3palbociclib 3abemaciclib 3Anastrozole 3Trastuzumab 2Letrozole 2Gonadotropin-Releasing Hormone 2AZD9833 2tucatinib 1trastuzumab deruxtecan 1taxane 1pertuzumab 1pembrolizumab 1ipatasertib 1figitumumab 1elacestrant 1dactolisib 1atezolizumab 1Watchful Waiting 1Trabectedin 1Tamoxifen 1STX-478 1RAD1901 1Paclitaxel 1Metformin 1Lapatinib 1Imlunestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Diseases × 2,2'-dithiodiethanesulfonic acid × Clear all
NCT00039780 2022-07-13

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
764 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Paresthesia, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡